Refine
Year of publication
Document Type
- Doctoral Thesis (41)
Language
- English (41) (remove)
Has Fulltext
- yes (41)
Is part of the Bibliography
- no (41)
Keywords
- ABC-Transporter (3)
- ABC-transporter (1)
- ABCE1 (1)
- ATP-Binding Cassette Transporter (ABC) (1)
- ATPase (1)
- Adenosintriphosphatasen (1)
- Biophysik (1)
- Biosensorik (1)
- Blutgefäß (1)
- Blutgefäßsystem (1)
Institute
- Biochemie und Chemie (23)
- Biochemie, Chemie und Pharmazie (15)
- Pharmazie (2)
- Biowissenschaften (1)
- Georg-Speyer-Haus (1)
The adaptive immune system protects against daily infections and malignant transformation. In this, the translocation of antigenic peptides by the transporter associated with antigen processing (TAP) into the ER lumen is an essential step in the antigen presentation by MHC I molecules. The heterodimeric ATP-binding cassette transporter (ABC) TAP consist of the two halftransporters TAP1 and TAP2. Each monomer contains an N-terminal transmembrane domain (TMD) and a conserved C-terminal nucleotide-binding domain (NBD). Together, the TMDs build the translocation core and the NBDs bind and hydrolyze ATP, energizing the peptide transport. TAP features an asymmetry in the two ATP-binding sites that are built of several conserved motifs. One motif is the D-loop with the consensus sequence SALD. The highly conserved aspartate of the D-loop of TAP1 reaches into the canonic ATP-binding site and contacts the Walker A motif and the H-loop of the opposite NBD, while the Asp of D-loop of TAP2 is part of the non-canonic ATP-binding site.
To examine this ABC transport complex in mechanistic detail, a purification and reconstitution procedure was established with the function of TAP being preserved. The heterodimeric TAP complex was purified via a His10-tag at TAP1 in a 1:1 ratio of the subunits. Nucleotide binding to the purified transporter was elucidated by tryptophan quenching assays and the affinity constants for MgADP and MgATP were determined to be 1.0 μM and 0.7 μM, respectevely. In addition, the TAP complex shows strict coupling between peptide binding and ATP hydrolysis, revealing no basal ATPase activity in the absence of peptides. Furthermore, TAP was reconstituted into proteoliposomes and the activity was tested by peptide transport and ATP hydrolysis. Interestingly, the kinetic parameters of the transporter in the reconstituted state are comparable to the data gained for TAP in microsomes.
To characterize the functional importance of the D-loop, D-loop mutants of either TAP1 or TAP2 were analyzed. Strikingly, TAP containing a mutated D-loop in TAP1 (D674A) shows an ATP-hydrolysis independent peptide translocation. Accordingly, the MHC I surface expression is similar to the wildtype situation. However, the same mutation in TAP2 (D638A) results in an ATPase dependent peptide transport similar to wildtype, whereas TAP containing mutations in both subunits leads to an inactive transporter. Although all D-loop mutants showed no altered peptide binding activity, the TAP1 mutant is inactive in peptide-stimulated ATPase activity. Strikingly, ATP or ADP binding is strictly required for the peptide translocation. Experiments carried out in proteoliposomes demonstrate that wildtype TAP can export peptides against their gradient when low peptide concentrations are offered. In contrast, the D674A mutant can facilitate peptide translocation along their concentration gradient in the two directions. At high peptide concentrations, TAP is trapped in a transport incompetent state induced by trans-inhibition. In conclusion, a TAP mutant that uncouples solute translocation from ATP hydrolysis was created. Since this passive substrate movement is strictly dependent on binding of ATP or ADP, an active transporter was turned into a “nucleotide-gated facilitator”.
In a cysteine cross-linking approach the conformational changes of TAP during peptide transport and the flexibility of the nucleotide binding domains were examined. Single cysteines were introduced in the D-loops of TAP1 and TAP2. Cross-linking by copper-phenantroline (CuPhe) was possible for all combinations. However, by adding ATP, ADP or peptide to the TAP complex no differences in the cross-linking efficiency were detected. By CuPhe cross-linking TAP was trapped in a conformation, in which the peptide binding site was not accessible. To complete a transport cycle, a flexibility of at least 17.8 Å of the NBDs is needed, since TAP cross-linked by CuPhe (2.0 Å) or bismaleimidoethane (BMOE, 8.0 Å) was transport inactive but when TAP was cross-linked by 1,11-bismaleimido-triethyleneglycol (BM[PEG]3, 17.8 Å) transport activity was preserved.
Presentation of intracellular processed antigens by major histocompatibility (MHC) class I molecules to CD8+ cytotoxic T lymphocytes is mediated by the macromolecular peptide loading complex (PLC). In particular accessory proteins, including the transporter associated with antigen processing (TAP) and tapasin, play a pivotal role in the MHC class I mediated antigen presentation pathway. TAP belongs to the ATP-binding cassette (ABC) superfamily and consists of TAP1 (ABCB2) and TAP2 (ABCB3), each of which possesses a transmembrane and a nucleotide-binding domain (NBD). The ER-resident glycoprotein tapasin promotes the optimal folding and assembly of MHC-peptide complexes, and independently stabilizes the steady state expression level of TAP. In the present thesis recombinant Fv, scFv and Fab antibody fragments to human TAP from a hybridoma cell line expressing the TAP1-specific monoclonal antibody mAb148.3, were generated. The epitope of the mAb148.3 was mapped to the very last five C-terminal amino acid residues of TAP1 on solid-supported peptide arrays. The recombinant antibody fragments were heterologously expressed in E. coli and insect cells, and purified to homogeneity by affinity chromatography. The monoclonal and recombinant antibodies display nanomolar affinity to the last five C-terminal amino acid residues of TAP1 as demonstrated by enzyme linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). Surprisingly, the recombinant antibody fragments confer thermal stability to the heterodimeric TAP complex in insect cells when incubated at elevated temperature. At the same time, TAP is arrested in a peptide transport incompetent conformation, although ATP and peptide binding to TAP are not affected. Furthermore, the recombinant antibodies were successfully used in the purification of the PLC from a human B-lymphoblastoid cell line and a novel factor, protein disulfide isomerase (PDI), was identified by matrix assisted laser desorption/ionisation-mass spectrometry (MALDI-MS). In the second part of this thesis the tapasin-MHC class I interaction was investigated. It is for this reason, that an in vitro assay had been established for direct measuring tapasin-MHC class I interactions. First, soluble single chain MHC class I molecules were engineered, choosing two MHC class I alleles: HLA-B4402 representing a highly tapasin-dependent allele and with HLA-B4405, a tapasin-independent allele was chosen. Tapasin as well as the two single chain MHC class I constructs, scB4402-b2m and scB4405-b2m, were expressed in insect cells and purified from insect cell supernatants by affinity chromatography. In contrast to the HLA-B4405 allele, which was expressed and secreted at moderate yield, the HLA-B4402 allele was expressed and trapped inside the insect cells instead of secreted into the medium. Peptide-binding and anisotropy measurements with fluorescein-labeled peptides verified the functionality of the scB4405-b2m. For further investigation of the tapasin-MHC class I interaction an in vitro assay was established using surface plasmon resonance spectroscopy. Due to the transient nature of the interaction including the decreased affinity of both interaction partners, kinetic data acquisition was difficult to evaluate. Furthermore, interaction of the scB4405-b2m with the sensor surface itself contributed to the measured interaction. Additionally, to investigate tapasin editing function, tapasin as well as the scB4405-b2m-peptide complex were tethered on fluid chelator lipid bilayers and monitored by reflectance interference (RIf) and total internal reflection fluorescence spectroscopy (TIRFS). Stable immobilization of scB4405-b2m-peptide complex as well as of tapasin was observed, unfortunately no changes in peptide dissociation kinetics monitored in the TIRFS channel were detected. Presumably, the tapasin-independent HLA-B4405 already loaded with a high affinity peptide is not influenced by the peptide-editing function of tapasin. Here, for the first time an in vitro assay was established for direct probing interactions within the various proteins of the PLC.
Two distinct mechanisms contribute to the development of blood vessels: vasculogenesis, which is the de novo formation of vascular structures from progenitor cells, and angiogenesis, the formation of new blood vessels from pre-existing ones.
Angiogenesis is a highly ordered and carefully regulated multi-step process, during which the precise spatio-temporal interaction between endothelial and mural cells, i.e. smooth muscle cells and pericytes, is prerequisite for the formation of a functional blood vessel. The crosstalk between these two latter cell ty pes is mediated indirectly by various
secreted growth factors, and directly through cell-cell and cell-matrix interactions. The secretory epidermal growth factor-like protein 7 (EGFL7) has been implicated to
play an important role in the regulation of smooth muscle and endothelial cell recruitment and vascular tube formation. However, in-depth investigation of the underlying molecular mechanism has so far been hampered by the lack of functional recombinant EGFL7. In this study for the first time full length EGFL7 was successfully expressed as a His 6- tagged fusion protein from insect cells using the Baculovirus expression vector system. Recombinant EGFL7 was purified in a two-step protocol involving ion metal affinity chromatography and gel filtration. Furthermore, recombinant EGFL7 was
purified from human embryonic kidney EBN A 293 cells using a similar approach, allowing the production of high amounts of recombinant EGFL7 protein in its native state, with proper post-translational processing and full biological activity. Detailed analysis of the post-translational processing of recombinant EGFL7 and EGFL7-mutants revealed extensive proteolytic processing by protein convertases both at the N- and the C-terminus, the latter being prerequisite for EGFL7 secretion. Furthermore, secreted EGFL7 protein was shown to bind to the extracellular matrix and the responsible heparin-binding domain of EGFL7 was mapped to its N-terminal
portion. Purified recombinant EGFL7 protein was tested for its functionality using cell migration assays, cell proliferation studies and in vivo matrigel studies in mice. In the
modified Boyden chamber migration assay, recombinant EGFL7 proteins inhibited PDGF-BB-induced smooth muscle cell migration. Moreover, recombinant EGLF7 proteins strongly inhibited PDGF-BB-induced proliferation of smooth muscle cells, while it did not affect VEGF induced proliferation of endothelial cells. When applied in the in vivo matrigel plug assay, EGFL7 proteins induced a strong pro-angiogenic response, comparable with that of VEGF on an equimolar basis. Moreover, EGFL7 expression was strongly induced in endothelial cells in response to VEGF stimulation. These novel findings demonstrate the important function of EGFL7 in angiogenesis and are well in line with previous results. They demonstrate a cell specific action of EGFL7 on the different cell types involved in vessel formation, which is a prerequisite for a regulatory function in cell-to-cell crosstalk. Based on the results described here, the following model can be proposed: VEGF, a known strong initiator of angiogenesis, induces endothelial cell proliferation and migration, allowing the
escape from the comparatively rigid structure of a functional vessel to form an angiogenic sprout. At the same time VEGF induces the expression of EGFL7 in endothelial cells. EGFL7 is expressed, proc essed and secreted from these cells. While EGFL7 has no known effect on endothelial cells, it inhibits smooth muscle cell proliferation and migration, providing a mechanism to prevent pre-mature stabilization of the forming vessel. The availability of purified recombinant EGFL7 will be helpful in the detailed characterization of the underlying molecular mechanism of EGFL7 action, including the identification of the putative EGFL7 receptor, and will allow - together with knock-out experiments in mice - the exploration of the additional biological functions of EGFL7. Moreover, considering the strong pro-angiogenic effect of EGFL7 in vivo, it would be also of a great therapeutic interest to investigate its role in the development of tumor vasculature. The insights into these molecular mechanisms might provide a novel approach for the development of anti tumor therapies.
Biophysical investigation of the ligand-induced assembling of the human type I interferon receptor
(2005)
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory responses through binding to a shared receptor consisting of the transmembrane proteins ifnar1 and ifnar2. Differential signaling by different interferons – in particular IFNalpha´s and IFNbeta – suggest different modes of receptor engagement. In this work either single ligand-receptor interactions or the formation of the extracellular part of a signaling complex were investigated referring to thermodynamics, kinetics, stoichiometry and structural organization. Initially an expression and purification strategy for the extracellular domain of ifnar1 (ifnar1-EC) using Sf9 insect cells yielding in mg amounts of glycosylated protein was established. Using reflectometric interference spectroscopy (RIfS) the interactions between IFNalpha2/beta and ifnar1-EC and ifnar2-EC was studied in order to understand the individual energetic contributions within the ternary complex. For IFNalpha2 a Kd of 5 µM for the interaction with ifnar1-EC was determined. Substantially tighter binding of IFNbeta with both ifnar2-EC and ifnar1-EC compared to IFNalpha2 was observed. For neither IFNalpha2 nor IFNbeta stabilization of the complex with ifnar1-EC in presence of soluble ifnar2-EC was detectable. In addition, no direct interaction between ifnar2 and ifnar1 was could be shown. Thus, stem-stem interactions between the extracellular domains of ifnar1 and ifnar2 do not seem to play a role for ternary complex formation. Furthermore, ligand-induced cross-talk between ifnar1-EC and ifnar2-EC being tethered onto solid-supported, fluid lipid bilayers was investigated by RIfS and total internal reflection fluorescence spectroscopy. A very stable binding of IFNalpha2 at high receptor surface concentrations was observed with an apparent kd approximately 200-times lower than for ifnar2-EC alone. This apparent kd was strongly dependent on the surface concentration of the receptor components, suggesting kinetic rather than static stabilization, which was corroborated by competition experiments. These results indicate that signaling is activated by transient cross-talk between ifnar1 and ifnar2, which is by several orders of magnitude more efficiently engaged by IFNbeta than by IFNalpha2. With respect to differential recognition of different IFNs ifnar1-EC was dissected into sub-fragments containing different of the four Ig-like domains. The appropriate folding and glycosylation of these proteins, also purified in mg amounts were confirmed by SDS-PAGE, size exclusion chromatography and CD-spectroscopy. Surprisingly, only one construct containing all three N-terminal Ig-like domains was active in terms of ligand binding, indicating that these domains were required. Competitive binding of IFNalpha2 and IFNbeta to both this fragment and ifnar1-EC was demonstrated. Cellular binding assays with different fragments, however, highlight the key role of the membrane-proximal Ig-like domain for the formation of an in situ IFN-receptor complex and the ensuing signal activation. Even substitution with Ig-like domains from homologous cytokine receptors did not restore high-affinity ligand binding. Receptor assembling analysis on supported lipid bilayer revealed that appropriate orientation of the receptor is required, which is controlled by the membrane-proximal Ig-domain. All results indicate that differential signalling is encoded by the efficiency of signalling complex formation, which is controlled by the binding affinity of IFNs to the extracellular domains of ifnar1 and 2.
LmrA is a member of the ATP Binding Cassette (ABC) transporter family of membrane proteins and a structural and functional homologue of P-glycoprotein1, 2. ABC-transporters share a common architecture of two transmembrane domains and two nucleotide binding domains. The NBDs are highly conserved in this transporter family whereas the TMDs are highly diverse3. The TMDs recognize the substrate and the NBDs bind and hydrolyze ATP and thus contribute the energy for substrate translocation. ABC transporters as a protein family transport a high number of substrates including peptides, nutrients, ions, bile acids, lipids and other lipophilic compounds. LmrA is a multidrug transporter that recognizes a number of hydrophobic substrates including fluorescent dyes and antibiotics1, 4-6. LmrA is a native protein of the gram-positive bacterium Lactococcus lactis. In this thesis, L. lactis was used as a homologous expression host for the preparation of LmrA for a variety of experiments. Wildtype LmrA as well as a number of cysteine mutants were successfully expressed in L. lactis, purified and subsequently characterized by a variety of biochemical assays (Chapter 4). LmrA can be expressed to very high amounts in L. lactis. The purification and reconstitution were optimized for the requirements of solid-state NMR experiments in this thesis. For the first time, an ABC transporter has been reconstituted in synthetic lipids to a ratio of up to 1:150 (mol/mol). LmrA was shown to be active under magic angle spinning conditions with these reconstitution ratios. By taking advantage of the slower ATP hydrolysis by LmrA ΔK388 (lysine deletion in the Walker A motif), a real-time 31P solid-state NMR ATPase assay was established (Chapter 5). This assay allowed, for the first time, the investigation of all phosphor nuclei during the ATP hydrolysis cycle of a membrane protein simultaneously and in real time7. This assay has been successfully adapted to investigate both ATP hydrolysis and substrate phosphorylation of diacylglycerol kinase (together with S. Wollschlag) and ATP hydrolysis at high temperatures of the thermophilic ABC transporter ABC1 from Thermos thermophilus (together with A. Zutz). In the course of this thesis, the gene for LmrA has been cloned into expression vectors suitable for Escherichia coli and the heterologous expression of LmrA was established (Chapter 4). The functionality of the heterologously expressed protein has been investigated and compared to L. lactis LmrA. In these experiments, LmrA was shown to yield a distinct multidrug resistance phenotype in its E. coli host and to show secondary active multidrug transport in the absence of ATP and presence of a proton gradient [Hellmich et al, in prep] (Chapter 4). Previously, it had been shown that LmrA acts as a seconadary active transporter when the NBDs are truncated8. The overexpression in minimal and defined medium and the purification of LmrA from E. coli have been optimized. Isotope labeling for ssNMR has been established and the first multinuclear ssNMR experiments have been carried out on a functional ABC transporter (Chapter 8). ABC transporters couple two cycles: upon ATP binding, the NBDs dimerize, hydrolyze the ATP, subsequently release Pi and ADP and finally dissociate. During this cycle, conformational changes are relayed to the TMDs which utilize the energy from ATP binding and/or hydrolysis to translocate the respective substrate. The prehydrolysis state can be trapped by beryllium fluoride, whereas the post-hydrolysis state of this cycle can be trapped by vanadate9-12. Trapping protocols for these reagents were successfully established for LmrA in this thesis (Chapter 4). This allowed for the investigation of different catalytic states by both ssNMR and EPR. A general 19F labeling protocol for membrane proteins has been established in the course of this thesis and successfully applied to proteorhodopsin (together with N. Pfleger)13 and LmrA (chapter 6). Single cysteine mutants of LmrA that line out the dimer interface have been labeled with a fluorine label for ssNMR. In the apo state, the 19F labeling indicates highly flexible transmembrane domains, a finding that is supported by 13C ssNMR and EPR measurements. The addition of drugs has a different effect on different positions within the LmrA dimer, therefore indicating that different drugs are recognized at a different position within the protein. For P-glycoprotein and LmrA it has been previously shown by biochemical methods that different drug binding sites co-exist. For a 19F label attached at position 314 (LmrA E314C), the spectra showed two distinct peaks with similar populations. This could hint towards a structural asymmetry within the LmrA dimer that might also be reflected in the alternating ATP hydrolysis at the NBDs. E314 has been specifically implicated with drug transport. Thus, structural asymmetry at this position might be functionally relevant for guiding a substrate through the transporter. Structural asymmetry within a homodimeric ABC transporter has also been shown for BtuCD, the E. coli vitamin B12 importer14. In addition, the conserved glutamates in EmrE, a small multidrug resistance protein, were shown to be asymmetric in the drug bound state15. Both, uniformly 13C/15N labeled as well as selectively amino acid type labeled LmrA has been investigated in different conformational states. Interestingly, significant dynamic changes in the b-sheet regions of LmrA (confined to the NBDs) were observed in the pre-hydrolysis (beryllium fluoride) and transition state (vanadate trapped) state. These were interpreted as the transition from a domain in fast conformational exchange in the apo state to one of intermediate exchange in the nucleotide bound state. A significant change in NBD mobility upon nucleotide binding was previously also shown with 2H ssNMR on LmrA16. By EPR it was shown that LmrA in both the vanadate and BeFx trapped states displays a significantly higher rigidity and therefore defined distances, whereas the apo state resembled a “floppy” protein with no preferred distance distribution. This concurs with data obtained from 19F ssNMR with fluorine labeled single-cysteine mutants. Here, in agreement with the EPR data, a higher label (and possibly) protein mobility was observed in the apo state displaying rather broad line widths. Upon trapping with vanadate, the line widths of the majority of fluorine-labeled mutants decreased due to an enhanced protein rigidity and a more homogenous environment of the fluorine labels. A similar observation was made when increasing the temperature that can be explained due to higher protein flexibility at increased temperatures. Solution NMR was employed to investigate the isolated soluble NBD of LmrA (Chapter 9). First 2D and 3D spectra were successfully obtained and could be utilized for a preliminary assignment of a significant fraction of residues. Additionally, binding of ATP and ADP in absence and presence of magnesium was investigated. Finally, the effects of peptides emulating the coupling helices of the full-length transporter on the soluble NBD were investigated. Strikingly, binding of one of these peptides only occurred in the presence of nucleotides (whereas the other showed no binding at all) hinting towards a tightly coupled regulation of the NBD and TMD during the substrate translocation/ATP hydrolysis cycle based on nucleotide binding.
Characterization of mouse NOA1 : subcellular localizaion, G-Quadruplex binding and proteolysis
(2013)
Mitochondria contain their own protein synthesis machinery with mitoribosomes that are similar to prokaryotic ribosomes. The thirteen proteins encoded in the mitochondrial genome are members of the respiratory chain complexes that generate a proton gradient, which is the electromotoric force for ATP synthesis.
NOA1 (Nitric Oxide Associated Protein-1) is a nuclear encoded GTPase that positively influences mitochondrial respiration and ATP production. Although a role in mitoribosome assembly was assigned to NOA1 the underlying molecular mechanism is poorly understood. This work shows that the multi-domain protein NOA1 serves multiple purposes for the function of mitochondria. NOA1 is a dual localized protein that makes a detour through the nucleus before mitochondrial import. The nuclear shuttling is mediated by a nuclear localization signal and the now identified nuclear export signal. SELEX (Systemic Evolution of Ligands by Exponential Enrichment) analysis revealed a G-quadruplex binding motif that characterizes NOA1 as ribonucleoprotein (RNP). G-quadruplex binding was coupled to the GTPase activity and increased the GTP hydrolysis rate. The sequence of localization events and the identification of NOA1 being a RNP lead to the discussion of an alternative import pathway for RNPs into mitochondria. The short-lived NOA1 contains ClpX recognition motifs and is specifically degraded by the mitochondrial matrix protease ClpXP. NOA1 is the first reported substrate of ClpXP in higher eukaryotes and augments the contribution of the ClpXP protease for mitochondrial metabolism. To assess the direct action of NOA1 on the mitoribosome co-sedimentation assays were performed. They showed that the interaction of NOA1 and the mitoribosome is dependent on the GTPase function and the nascent peptide chain. In vitro, NOA1 facilitated the membrane insertion of newly translated and isotope labeled mitochondrial translation products into inverted mitochondrial inner membrane vesicles. In conclusion, NOA1 is a G-quadruplex-RNP that acts as mitochondrial membrane insertion factor for mtDNA-encoded proteins.
This thesis provides a comprehensive model of the molecular function of NOA1 and is the basis for future research. The identification of NOA1 as ClpXP substrate is a major contribution to the field of mitochondrial research.
Paramyxo- and pneumoviruses include many pathogens with great relevance for human and animal health. To identify common host factors involved in the Paramyxo- and Pneumoviridae life cycle as a basis for new insights in the biology of these viruses and the development of rationally designed therapeutics, genome scale siRNA screens with wild-type measles, mumps, and respiratory syncytial viruses in A549 cells, a human lung adenocarcinoma cell line, were performed. A comparative bioinformatics analysis yielded different members of the coatomer complex I, the translation factors ABCE1 and eIF3A, and several RNA binding proteins as cellular proteins with proviral activity for all three viruses. The strongest common hit, ABCE1, an ATP-binding cassette transporter member, was chosen for further study. We found that ABCE1 supports replication of all three viruses, confirming its importance for both virus families. While viral protein kinetics showed that ABCE1 knockdown resulted in a drastic decrease of MeV protein expression, viral mRNA kinetics are not directly affected by a reduction of ABCE1.
The impact of ABCE1 on viral and global cellular translation was investigated using both 35S metabolic labelling and non radioactive fluorescent protein labelling. ABCE1 knockdown strongly inhibited the production of MeV proteins, while only modestly affecting global cellular protein synthesis and showed that ABCE1 is specifically required for efficient viral, but not general cellular, protein synthesis, indicating that paramyxoand pneumoviral mRNAs may exploit specific translation mechanisms.
In a second approach the efficacy of the small-molecule polymerase inhibitor ERDRP-0519 against MeV was assessed in squirrel monkeys. Animals treated with the drug experienced less severe clinical disease compared to untreated controls, and this effect correlated with the onset of drug treatment.
We observed a reduction of levels of PBMC-associated viremia and virus release in the upper airways, illustrating effective inhibition of virus replication by the drug treatment. ERDRP-0519 drug treatment also alleviated MeV-induced immunosuppression. In addition to providing proof-of-concept for the support of MeV eradication efforts by preventing disease and transmission with a small-molecule polymerase inhibitor, this dissertation provides a novel perspective on cellular proteins that impact the replication of MeV, MuV and HRSV and highlights the role of ABCE1 as host factor that is required for efficient paramyxo- and pneumovirus translation.
The detailed mechanism of the 20 S proteasome from Thermoplasma acidophilum is unknown. Substrates are degraded processively to small fragments without the release of intermediates, but the basis for this unique degradation mode remains obscure. The proteasome is a molecular machine, but how the different nanocompartments interplay and whether more than one substrate can be treated simultaneously has not been elucidated yet. To address these questions we had to disable the functionality of one aperture in order to dissect whether the other pore can compensate for the loss. As it is challenging to introduce mutations solely around one pore aperture of the highly symmetrical construct, we chose a novel approach by unique orientation of the proteasome at interfaces. For this purpose we purified recombinant 20 S proteasomes, where hexahistidine tags were fused either around the entrances or at the sides. According to electron microscopic studies we immobilized these constructs uniformly either end-on or side-on at metal-chelating interfaces (lipid vesicles, lipid monolayers and self-assembled thiol monolayers). Degradation of small fluorogenic peptides and large proteins like casein was analyzed. Small substrates were degraded with comparable activity by free and immobilized proteasomes, irrespective of their orientation. Thus it can be assumed that peptides can pass the sealed entrance of the 'dead-end' proteasome. However, larger substrates like fluorescently labeled casein were processed near the temperature optimum by side-on immobilized and soluble proteasomes with threefold activity compared to end-on immobilized proteasomes. Hence it can be concluded that one pore is sufficient for substrate entry and product release. In other words, the pore and antechamber can fulfil a triple function in the import and unwinding of substrates and the egress of products. With means of surface plasmon resonance the exact substrate/proteasome stoichiometry could be determined to ~1 for 'dead-end' proteasomes and ~2 for side-on immobilized (active and inactive) proteasomes. Most importantly, a fit with the Hill equation revealed positive cooperativity for side-on immobilized (Hill coefficient ~2) in contrast to end-on immobilized proteasomes (Hill coefficient ~1). Thus in case of soluble proteasomes two substrates bind presumably in opposite antechambers with positive cooperativity. The off-rate of casein as substrate is twofold for the active side-on immobilized proteasome in comparison to the end-on immobilized proteasome. The exact 2:1 stoichiometry of the off-rates equals the ratio of exit pathways amenable in case of side-on orientated versus 'dead-end' immobilized proteasomes. Thus crevices along the cylindrical body of the 20 S proteasome seem not to participate in the egress of small products. An inactive proteasome mutant displays a concentration-dependent off-kinetic against casein. Accordingly, the off-rate of the bisubstrate:proteasome complex can be attributed around half the value of the monosubstrate:proteasome complex. Consequently, substrates exit the inactive proteasome via the route of access due to obstruction of the trans side with an entering substrate. Hence the active proteasomes have to chop substrates down to small fragments prior to release through both pores. Thus the processive degradation mode might result from positive binding cooperativity. The on-rate constants for casein suggested that substrate association represents a two-step process comprising a rate-limiting translocation step and a fast binding step. As fluorescence cross-correlation revealed that two substrates can be co-localized in the proteasome and bind successively with increasing affinity (KD,1 = 8 µM versus KD,2 = 700 nM), an allosteric transition in the proteasome can be assumed. Combining our results with the data from other research groups led to a mechanistic model for the 20 S proteasome. Accordingly, the first substrate undergoes a slow translocation step, binds in the antechamber and diffuses subsequently to the catalytic centers, where it is degraded. By switching on the catalytic activity, the pores at both termini are dilated via conformational changes. Hence entry of the second substrate into the proteasome is facilitated due to omission of the rate-determining translocation step. The second substrate is either accommodated in the antechamber before it is processed (alternating degradation) or, most probably, is directly threaded into the central cavity (simultaneous degradation). As effusing peptides compete with entering proteins for binding in the antechamber, the pores are kept in an open state. After finishing digestion the pores are closed and a new degradation cycle can be reinitiated. In summary, substrate association with the proteasome underlies an ordered alternating binding mechanism in contrast to the random mode of degradation. Thus the two-stroke engine offers the advantage of speeding up degradation without enhancing complexity.
Endolysosomal effectors and their relevance for antiviral activity against the Hepatitis E virus
(2021)
Mit über 20 Millionen registrierter Fälle pro Jahr, repräsentiert das Hepatitis-E-Virus (HEV) eine Hauptursache einer viralen Hepatitis weltweit und stellt ein erhebliches Risiko insbesondere für Schwangere und Immunsupprimierte dar. Jedoch sind Behandlungsoptionen stark limitiert und mit teils schweren Nebenwirkungen verbunden. Neue Erkenntnisse des Wechselspiels zwischen Wirtszelle und HEV werden deshalb benötigt, um neue antivirale Wirkstoffe zu entwickeln. Der Fokus der Arbeit wurde hierbei auf Effektoren des endosomalen Systems gesetzt, welches von HEV zur Freisetzung von Virionen genutzt wird.
Eine virale Infektion führt in der Zelle zur Produktion von Interferonen (IFNs) und weiters zu einer IFN-Antwort. Ein essenzielles Effektormolekül, welches HEV nachweislich effizient repressiert, ist die GTPase guanylate binding protein 1 (GBP1). In dieser Studie wurde beleuchtet, dass Letztere durch eine HEV-Infektion induziert wird. Zusätzlich reduziert die ektopische Expression von GBP1 sowohl die intrazelluläre Menge des HEV Kapsidproteins als auch die Menge freigesetzter Virionen. Mechanistisch liegt diesem Sachverhalt die GBP1-induzierte Inkorporation von Virionen in Lysosomen zugrunde, was schlussendlich deren Abbau nach sich zieht. Erkenntnisse über die Rolle verschiedener GBP1 Proteindomänen innerhalb des Mechanismus wurden unter Verwendung ektopischer Expression von GBP1-Mutanten erlangt. Inkorporation der Mutation R48A führt zum Verlust der GTPase-Aktivität. Andererseits führt eine Inkorporation der Mutation S73A zum Verlust der Homodimerisierung, was die nachfolgende Farnesylierung und gekoppelte Membranassoziation reduziert. Hierbei behält GBP1-R48A Fähigkeiten zur Induktion lysosomalen Abbaus von HEV bei, GBP1-S73A jedoch nicht. Dies wiederum bedeutet, dass eine GBP1 Homodimerisierung notwendig für den antiviralen Mechanismus ist, was eine Adapterfunktion des Moleküls für lysosomale Inkorporation nahelegt. Die Relevanz von GBP1 während einer IFNγ-Antwort wurde deshalb mittels siRNA-basiertem Silencing untersucht. Ähnlich der ektopischen Expression von GBP1 induziert IFNγ die lysosomale Degradation von HEV. In Abwesenheit von GBP1 jedoch, ist dieser Effekt signifikant geringer ausgeprägt, was zu einem Effizienzverlust von IFNy in Bezug auf dessen antiviralen Effekt bedeutet. Dies führte schlussendlich zur Identifizierung von GBP1 als essenziellen Restriktionsfaktor gegen HEV, was seine Rolle in Abhängigkeit seiner Homodimerisierung via Induktion lysosomalen Abbaus erfüllt.
Nebst der Induktion von GBP1, konnte eine Akkumulation von Cholesterin in Lysosomen durch IFNy nachgewiesen werden. Da dieses Lipid einen essenziellen Faktor für endosomale Reifung, Transport und Funktionalität darstellt, wurden Cholesterinspiegel und verbundene transkriptionelle Fußabdrücke im Kontext einer HEV Infektion untersucht. Letztere führt zu einer Dysregulation Cholesterin-assoziierter Genexpression, was eine Reduktion intrazellulären Cholesterins nach sich zieht. Auch in HEV infizierten Patienten liegt eine Abnahme des Serumcholesterins vor. Unter Modulation intrazellulären Cholesterins, wurde deutlich, dass die Inhibition der Cholesterinsynthese durch Simvastatin eine verstärkte Freisetzung von Virionen nach sich zieht, was ebenso in HEV infizierten Patienten nachweisbar war. Im Gegensatz hierzu zieht eine Erhöhung intrazellulären Cholesterins via Supplementierung von Lipoproteinpartikeln niedriger Dichte (LDL) oder 25-Hydroxycholesterin eine signifikante Reduktion des viralen Kapsidproteins und freigesetzter Virionen nach sich. Dem liegt eine verstärkte Inkorporation von HEV in Lysosomen mit anschließender Degradation zugrunde. Ob dieser Mechanismus pharmakologisch nutzbar ist, wurde mittels eines Screenings Lipid modulatorischer Medikamente untersucht. Der p-Glykoprotein Inhibitor PSC833 und besonders der PPARα-Agonist Fenofibrat stellten sich als äußerst effiziente Inhibitoren des HEV heraus. Beide führen zu einer Erhöhung und Akkumulation zellulären Cholesterins in vesikulären Strukturen. Dies zieht eine dramatische Erhöhung lysosomaler Lokalisation von HEV nach sich und führt letzten Endes zu einer signifikanten Reduktion freigesetzter Virionen.
Zusammenfassend konnten in dieser Studie essenzielle Funktionen von GBP1 in Bezug auf dessen restriktiven Effekt gegen HEV identifiziert werden. Weiters wurde dieses als entscheidender Wirtsfaktor für die IFNγ-Antwort gegen das Virus identifiziert. Andererseits legt diese Studie nahe, dass HEV niedrige Cholesterinspiegel innerhalb infizierter Zellen für die Freisetzung von Virionen benötigt. Andererseits sind erhöhte intrazelluläre Cholesterinspiegel schädlich für die virale Freisetzung, da der lysosomale Abbau von Virionen induziert wird. Dies führte zur erfolgreichen Entdeckung eines neuartigen antiviralen Wirkstoffes, welcher diesen cholesterinabhängigen Effekt effizient induziert: Fenofibrat.
As central component of the peptide loading complex, the ABC transporter TAP is a key player in the adaptive immune response. By recognizing and translocating antigenic peptides derived from proteasomal degradation into the ER lumen it connects the processing of harmful intruders and the marking of an infected cell for elimination. This work focused mainly on the interaction between TAP and one of its viral inhibitors. Of the five known TAP inhibitors, ICP47 is the only one that is not anchored in the ER membrane and has a nonomolar affinity to TAP. These properties and its specific architecture make it an interesting protein engineering tool that can be used in a variety of ways to generate functionally arrested TAP complexes. Different lengths of ICP47 were chosen to map the optimal distance between the binding pocket and the N-terminal elbow helix of either TAP1 or TAP2. I demonstrated that the interaction of fused ICP47 with coreTAP inhibits antigen presentation via MHC I. Interestingly, the loss of MHC I surface expression only depended on the presence of the active domain and not on the length of the fused ICP47 fragments. Summarizing it can be said that TAP complexes containing an intact active domain of ICP47 successfully suppressed MHC I surface expression. Considering the MHC I surface expression in the use of free ICP47 fragments it was revealed that the active domain may not be sufficient. All free constructs, except the one that contains exclusively the active domain (1-35), were able to fully arrest peptide translocation, while the fragment 1-35 partially restored MHC I surface expression. This was the first evidence suggesting that more residues might be present in the ICP47 sequence that contribute to the interaction with TAP.
Further characterization of the ICP47-coreTAP fusion complexes comprised the determination of their thermostability and melting temperatures. The ICP47-coreTAP fusion complexes revealed a preferred orientation for ICP47. The ICP47(1-65) fragment led to a stable complex only if fused to TAP2, highlighting an interesting asymmetry at the TAP1/TAP2 interface, which suggests a shorter distance of the C-terminus of the stabilizing region to the elbow helix of TAP2 than of TAP1. The shorter fragments 1-35 and 1-50, and the ICP47 linker fragments, which inhibited, but did not trigger any thermostabilizing effects on TAP, revealed a second hint for the presence of other residues important for the ICP47/TAP interaction. To define the thermostability in more detail, the melting temperature of complexes with fused or freely bound ICP47 fragments was determined. Short fused fragments of ICP47 (residues 1-35 or 1-50) did not fully stabilize the TAP complex. Only ICP47 fragments longer than residues 1-50 raised the melting temperature to the full extent and led to a completely stabilized complex, suggesting that the critical melting temperature, which determines whether a complex is fully stabilized or not, is about 44-45°C. By comparing different ICP47 proteins from the herpesviral clade, I further noticed that the 21 residues following the active domain are highly conserved. The residues in this region were exchanged by glycines and alanines to study their impact on the thermostabilization of TAP. I demonstrated that several charged residues, an alanine rich, and a proline rich sequence were mainly responsible for the preservation of high melting temperatures. In summary, these findings reveal a dual inhibition mechanism of ICP47. While the active domain of ICP47 is wedged at the TAP1/2 interface and arrests the complex in an open-inward facing conformation, the highly conserved C-terminal region stabilizes the ICP47/TAP interaction and generates a thermostabilized TAP complex.
The second part of this thesis deals with two alternative expression and stabilization strategies for coreTAP, designed to provide a 1:1 ratio of TAP subunits during protein biosynthesis. Different glycine-serine (GS) linkers and a self cleaving 2A site were im- plemented into the TAP sequence and used for comparison with the classical coreTAP. Despite their functionality in antigen translocation, the utilization of GS linkers proved to be unsuitable due to low expression and scarce purification efficiency caused by the unfeasible orthogonal purification. In contrast, the use of a 2A site allowed orthogonal His10- and SBP-tag purification and yielded comparable amounts to the classical coreTAP. However, the ICP47/coreTAP interaction appeared to be hampered by the modified N-terminus of ICP47, due to the cleavage process.
The third and last part of this work deals with the Thermus thermophilus ABC trans- porter TmrAB, which was identified to be part of the same ABC subfamily as TAP. The structure of TmrAB is similar to that of coreTAP and includes a TMD and an NBD for each subunit. In comparison to TAP, TmrAB has a broader substrate range, but it can transport peptides, which are also transported by TAP. Since the natural substrate, and thus the actual function, of TmrAB has not yet been identified, it is counted among the multidrug resistance ABC transporters, from where it also takes its name. In this work, the question was investigated whether TmrAB can be utilized as a TAP substitute. To compare the function of TmrAB and TAP in a natural cell environment, the N-terminal domains of the TAP subunits called TMD0s were fused to the TmrAB subunits and subsequently expressed as different combinations. I found that especially the hybrid complexes containing a TMD0 of TAP2 were functional in terms of MHC I surface expression. Furthermore, TmrAB with TMD0 co-localized prevalently with the ER marker PDI while complexes without TMD0 did not co-localize. Interestingly, the analysis of the interaction with components of the PLC revealed that interaction with tapasin could only occur when a TMD0 was present. In turn, calreticulin, MHC I, and ERp57 were bound, regardless of the presence of a TMD0. It is remarkable that a bacterial protein, sharing only 27-30% sequence identity with human TAP is able to take over a key function of our adaptive immune system. Yet, TmrAB originates from a hyperthermophilic bacterium and may have assembly and folding difficulties that the human cell seeks to overcome by recruiting chaperones like calreticulin and ERp57. Although further experiments will be necessary to analyze the interaction of TmrAB with the PLC components in more detail, TmrAB appears to be homologous to coreTAP, not only in terms of sequence and structure, but also in terms of function.